NERV News and Press, Minerva Neurosciences Inc From 11/07/23

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third qu...

2023-08-23 04:05:12 ET Summary Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments as...

2023-08-01 14:11:20 ET Minerva Neurosciences press release ( NASDAQ: NERV ): Q2 GAAP EPS of -$1.12. Cash, cash equivalents, and restricted cash as of June 30, 2023, were approximately $51.9 million, as compared to $36.2 million as of December 31, 2022. For further de...

BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second q...

2023-06-29 10:10:59 ET Gainers: RenovoRx ( RNXT ) +37% . Immunome ( IMNM ) +36% .  DermTech ( DMTK ) +15% . Galera Therapeutics ( GRTX ) +9% . Oncolytics Biotech ( ONCY ) +7% . Losers: BioXcel Therapeutics ( BTA...

2023-06-29 08:47:24 ET BioXcel Therapeutics ( BTAI ) -67% . announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation . CorMedix ( CRMD ) -21% on pricing $40M securities off...

Minerva Neurosciences, Inc. (NASDAQ: NERV) is one of today's top gainers. The company's shares are currently up 51.16% on the day to $9.1. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the tre...

2023-06-28 10:09:16 ET Gainers: Minerva Neurosciences ( NERV ) +51% . Regional Health Properties ( RHE ) +12% . Genfit ( GNFT ) +11% . RenovoRx ( RNXT ) +11% . OPKO Health ( OPK ) +5% . Losers: Cognition Therapeutics ( C...

2023-06-28 08:57:07 ET Biopharmaceutical company Minerva Neurosciences ( NASDAQ: NERV ) said on Wednesday that it is launching an ~$20M private investment in public equity, or PIPE, financing. The financing involves 1.43M shares at $10 per share and pre-funded warrants to...

BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 s...